A
Alvine Pharmaceuticals
An innovative biopharmaceutical company focused on autoimmune/inflammatory diseases
About Alvine Pharmaceuticals
LLCSwan, established in 2005 by Tina Crawford, is a premier content editing platform dedicated to enhancing the quality of written communication for businesses and individuals. The company operates in the content editing and legal services market, primarily serving small to medium-sized enterprises (SMEs) and individual entrepreneurs. LLCSwan specializes in providing comprehensive editing services that ensure clarity, coherence, and impact in all forms of written content. Additionally, the company offers guidance on forming limited liability companies (LLCs), helping clients navigate the complexities of legal structures and compliance with state and federal regulations.
LLCSwan's business model revolves around a subscription-based service, where clients pay a recurring fee for access to a suite of editing tools and personalized editing services. The company generates revenue through these subscriptions as well as one-time fees for specialized services such as legal document preparation and business incorporation assistance.
Operating in a competitive market, LLCSwan differentiates itself through its commitment to quality, customer satisfaction, and a deep understanding of the legal intricacies involved in business formation. The platform's user-friendly interface and expert editorial team make it a preferred choice for clients seeking reliable and efficient editing solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- San Carlos, United States
- Open positions
- None listed
- Dealroom signal
- 24.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2013 | $70M | $280M | Abbvie Biotech Ventures | — |
| DEBTDebt | Jan 2013 | $6M | — | Abbvie Biotech Ventures | — |
Growth signals
Latest recorded traffic for Alvine Pharmaceuticals is 730 monthly website visits, up 135.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Sofinnova Investments- PPProspect Venture Partners
Series B and later1 investor entered at this stage
Abbvie Biotech Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alvine Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alvine Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







